- SPANNR
- Posts
- Issue #36
Issue #36
Issue #36
February 2, 2023 | Issue #36
Good evening. And welcome to 100+ new subscribers who have joined since our last issue. We’re glad to have you. For those who missed last week's letter, here's another link to our recent 2022 Funding Report!In this week's newsletter: 🧠 LSD for Longevity?🔔 The newest longevity SPAC + other funding news📚 Weekend reading material
LSD: A Longevity Panacea or Pipedream?
LSD's history is complex.It gained popularity in the 1960s as a recreational drug among the counterculture and was even experimented with by the CIA for mind control.More recently, however, LSD has been undergoing a "rebrand" due to research by organizations like MAPS and efforts by individuals like Amanda Feilding to reform drug policy.So despite being once associated with "sex, drugs, and rock 'n' roll," LSD is now being seriously studied for its potential to treat not only anxiety but to... combat aging. The revival of LSD is part of a larger effort to tackle age-related diseases, including neurodegenerative diseases like Alzheimer's and Parkinson's, which currently have no cure.In our latest post, we talk more in-depth about LSD's potential benefits, including improvement of neuroplasticity, induction of synaptogenesis, and the reduction of inflammation... in addition to all the promising signs that make LSD's renaissance in the medical field worth watching.
VitaDAO, a community-owned collective funding early-stage longevity research, raises $4.1 million, backed by Pfizer Ventures and Balaji Srinivasan
Longevity Biomedical, a biopharmaceutical company focused on advancing new technologies across therapeutics, health monitoring and digital health solutions to increase human healthspan, plans to go public via SPAC
Levels, a software company that gives real-time feedback on how food affects a person's health, secures $7 million Series A extension funding to solve the metabolic health crisis
Elo, a smart nutrition company leveraging data from wearables, biomarker testing, and health questionnaires, raises a $10 million Series A and launches Smart Protein – the first wearable-powered protein formulated for optimal recovery
Metabolon, a company delivering biochemical data and insights to expand and accelerate the impact of life sciences research, announced that it has closed on $25 million of additional equity funding to accelerate growth
Precision Neuroscience, co-founded by Neuralink alum, raises $41 Million to build and scale the next generation of treatments for neurological illnesses
The Buck Institute launches first human clinical trial (Buck Institute)
NIH associate director announces departure to the private sector, joining anti-aging biotech (Endpts)
From Jeff Bezos to Jack Dorsey, here are 14 the world's wealthiest entrepreneurs trying to crack the code of living forever (Business Insider)
"Superager" genes can shave a decade off heart age, scientists say (Futurism)
Has the first person to live to be 150 been born? (The Harvard Gazette)
No more ‘playing God’: How the longevity field is trying to recast its work as serious science (STAT)
The time is now: Preparing for the economy of longevity (Mercer)
A common nail salon tool may cause DNA damage and mutations in human cells (CNN)
This Connecticut Metro Area Has the Longest Life Expectancy, Edging Out the Bay Area for No. 1 in the US (Moneygeek)
Performance:
Latest Price: $136.967d-Return: 7.05%Market Cap: $14.03b